LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 2 of total 2

Search options

  1. Article ; Online: Durable Humoral and Cellular Immune Responses 8 Months after Ad26.COV2.S Vaccination.

    Barouch, Dan H / Stephenson, Kathryn E / Sadoff, Jerald / Yu, Jingyou / Chang, Aiquan / Gebre, Makda / McMahan, Katherine / Liu, Jinyan / Chandrashekar, Abishek / Patel, Shivani / Le Gars, Mathieu / de Groot, Anne M / Heerwegh, Dirk / Struyf, Frank / Douoguih, Macaya / van Hoof, Johan / Schuitemaker, Hanneke

    The New England journal of medicine

    2021  Volume 385, Issue 10, Page(s) 951–953

    MeSH term(s) Ad26COVS1 ; Antibodies, Neutralizing/blood ; Antibodies, Viral/blood ; COVID-19 Vaccines/immunology ; Follow-Up Studies ; Humans ; Immunity, Cellular ; Immunity, Humoral ; Immunogenicity, Vaccine ; SARS-CoV-2 ; T-Lymphocytes/physiology ; Vaccination
    Chemical Substances Ad26COVS1 (JT2NS6183B) ; Antibodies, Neutralizing ; Antibodies, Viral ; COVID-19 Vaccines
    Language English
    Publishing date 2021-07-14
    Publishing country United States
    Document type Letter ; Research Support, Non-U.S. Gov't
    ZDB-ID 207154-x
    ISSN 1533-4406 ; 0028-4793
    ISSN (online) 1533-4406
    ISSN 0028-4793
    DOI 10.1056/NEJMc2108829
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Ua VI Zs.34: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  2. Article ; Online: Interim Results of a Phase 1-2a Trial of Ad26.COV2.S Covid-19 Vaccine.

    Sadoff, Jerald / Le Gars, Mathieu / Shukarev, Georgi / Heerwegh, Dirk / Truyers, Carla / de Groot, Anne M / Stoop, Jeroen / Tete, Sarah / Van Damme, Wim / Leroux-Roels, Isabel / Berghmans, Pieter-Jan / Kimmel, Murray / Van Damme, Pierre / de Hoon, Jan / Smith, William / Stephenson, Kathryn E / De Rosa, Stephen C / Cohen, Kristen W / McElrath, M Juliana /
    Cormier, Emmanuel / Scheper, Gert / Barouch, Dan H / Hendriks, Jenny / Struyf, Frank / Douoguih, Macaya / Van Hoof, Johan / Schuitemaker, Hanneke

    The New England journal of medicine

    2021  Volume 384, Issue 19, Page(s) 1824–1835

    Abstract: Background: Efficacious vaccines are urgently needed to contain the ongoing coronavirus disease 2019 (Covid-19) pandemic of infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). A candidate vaccine, Ad26.COV2.S, is a recombinant, ... ...

    Abstract Background: Efficacious vaccines are urgently needed to contain the ongoing coronavirus disease 2019 (Covid-19) pandemic of infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). A candidate vaccine, Ad26.COV2.S, is a recombinant, replication-incompetent adenovirus serotype 26 (Ad26) vector encoding a full-length and stabilized SARS-CoV-2 spike protein.
    Methods: In this multicenter, placebo-controlled, phase 1-2a trial, we randomly assigned healthy adults between the ages of 18 and 55 years (cohort 1) and those 65 years of age or older (cohort 3) to receive the Ad26.COV2.S vaccine at a dose of 5×10
    Results: After the administration of the first vaccine dose in 805 participants in cohorts 1 and 3 and after the second dose in cohort 1, the most frequent solicited adverse events were fatigue, headache, myalgia, and injection-site pain. The most frequent systemic adverse event was fever. Systemic adverse events were less common in cohort 3 than in cohort 1 and in those who received the low vaccine dose than in those who received the high dose. Reactogenicity was lower after the second dose. Neutralizing-antibody titers against wild-type virus were detected in 90% or more of all participants on day 29 after the first vaccine dose (geometric mean titer [GMT], 212 to 354), regardless of vaccine dose or age group, and reached 96% by day 57 with a further increase in titers (GMT, 288 to 488) in cohort 1a. Titers remained stable until at least day 71. A second dose provided an increase in the titer by a factor of 2.6 to 2.9 (GMT, 827 to 1266). Spike-binding antibody responses were similar to neutralizing-antibody responses. On day 15, CD4+ T-cell responses were detected in 76 to 83% of the participants in cohort 1 and in 60 to 67% of those in cohort 3, with a clear skewing toward type 1 helper T cells. CD8+ T-cell responses were robust overall but lower in cohort 3.
    Conclusions: The safety and immunogenicity profiles of Ad26.COV2.S support further development of this vaccine candidate. (Funded by Johnson & Johnson and the Biomedical Advanced Research and Development Authority of the Department of Health and Human Services; COV1001 ClinicalTrials.gov number, NCT04436276.).
    MeSH term(s) Ad26COVS1 ; Adolescent ; Adult ; Antibodies, Neutralizing/blood ; Antibodies, Viral/blood ; CD4 Lymphocyte Count ; CD4-Positive T-Lymphocytes/metabolism ; CD8-Positive T-Lymphocytes/metabolism ; COVID-19/immunology ; COVID-19/prevention & control ; COVID-19 Vaccines/administration & dosage ; COVID-19 Vaccines/adverse effects ; COVID-19 Vaccines/immunology ; Cohort Studies ; Double-Blind Method ; Humans ; Immunogenicity, Vaccine ; Male ; Middle Aged ; SARS-CoV-2/immunology ; Young Adult
    Chemical Substances Ad26COVS1 (JT2NS6183B) ; Antibodies, Neutralizing ; Antibodies, Viral ; COVID-19 Vaccines
    Language English
    Publishing date 2021-01-13
    Publishing country United States
    Document type Clinical Trial, Phase I ; Clinical Trial, Phase II ; Journal Article ; Multicenter Study ; Randomized Controlled Trial ; Research Support, Non-U.S. Gov't
    ZDB-ID 207154-x
    ISSN 1533-4406 ; 0028-4793
    ISSN (online) 1533-4406
    ISSN 0028-4793
    DOI 10.1056/NEJMoa2034201
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Ua VI Zs.34: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

To top